Department of Immunology and Infectious Diseases, Harvard T. H. Chan School of Public Health, Boston, United States; Center for Communicable Disease Dynamics, Harvard T. H. Chan School of Public Health, Boston, United States
Yi Wang
Department of Immunology and Infectious Diseases, Harvard T. H. Chan School of Public Health, Boston, United States
Daniel HF Rubin
Department of Immunology and Infectious Diseases, Harvard T. H. Chan School of Public Health, Boston, United States
Department of Immunology and Infectious Diseases, Harvard T. H. Chan School of Public Health, Boston, United States; Center for Communicable Disease Dynamics, Harvard T. H. Chan School of Public Health, Boston, United States; Division of Infectious Diseases, Brigham and Women’s Hospital, Harvard Medical School, Boston, United States
Increasing Neisseria gonorrhoeae resistance to ceftriaxone, the last antibiotic recommended for empiric gonorrhea treatment, poses an urgent public health threat. However, the genetic basis of reduced susceptibility to ceftriaxone is not completely understood: while most ceftriaxone resistance in clinical isolates is caused by target site mutations in penA, some isolates lack these mutations. We show that penA-independent ceftriaxone resistance has evolved multiple times through distinct mutations in rpoB and rpoD. We identify five mutations in these genes that each increase resistance to ceftriaxone, including one mutation that arose independently in two lineages, and show that clinical isolates from multiple lineages are a single nucleotide change from ceftriaxone resistance. These RNA polymerase mutations cause large-scale transcriptional changes without altering susceptibility to other antibiotics, reducing growth rate, or deranging cell morphology. These results underscore the unexpected diversity of pathways to resistance and the importance of continued surveillance for novel resistance mutations.